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Abstract: Pseudomonas aeruginosa is one of the major causes of morbidity and mortality of cystic
fibrosis patients. During the infection, the bacteria colonize the nutritional rich lung mucus, which is
present in the airway secretions in the patients, and they adapt their phenotype accordingly to the lung
environment. In the airways, P. aeruginosa undergoes a broad metabolic rewiring as a consequence of
the nutritional and stressful complexity of the lungs. However, the role of such metabolic rewiring
on the infection outcome is poorly understood. Here, we review the metabolic evolution of clinical
strains of P. aeruginosa during a cystic fibrosis lung infection and the metabolic functions operating
in vivo under patho-physiological conditions. Finally, we discuss the perspective of modeling the
cystic fibrosis environment using genome scale metabolic models of P. aeruginosa. Understanding the
physiological changes occurring during the infection may pave the way to a more effective treatment
for P. aeruginosa lung infections.
Keywords: metabolism; adaptation; evolution; cystic fibrosis; Pseudomonas aeruginosa
1. Introduction
Pseudomonas aeruginosa is an opportunistic pathogen with high medical importance. It is commonly
found in natural environments such as soils, plants, and waters but it can also cause diseases in
plants, animals, and humans [1]. The World Health Organization (WHO) included it in the list of
critical priorities due to its infecting capabilities and its multidrug resistance [2]. In Cystic Fibrosis
(CF) patients, P. aeruginosa causes long-term chronic airways infections, often lasting for more than
30 years. CF is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator
protein (CFTR) affecting the chloride ion channel activity. Such mutations, leading to an unfunctional
or misfolded CFTR transporter, cause dysregulation of the epithelial fluid transport with accumulation
of large amount of sticky and dehydrated mucus in the lungs [3]. While in healthy people the mucus
provides protection against inhaled particles and it is easily cleared through the mucociliary escalator,
its abnormal accumulation in CF patients causes breathing difficulties, persistent coughing and lung
inflammation such as bronchitis and infective pneumonia. Over time, this condition leads to reduced
lung function which will eventually lead to lung transplantation as a consequence of the progressive
respiratory failure. A detailed review of CF pathogenesis can be found in [4]. Since it contains variegated
and plentiful nutrients, the CF mucus constitutes an optimal substrate for bacterial growth [5]. P.
aeruginosa has a broad metabolic repertoire, which allows it to grow under different environmental and
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physiological conditions by employing its variegated catabolic and anabolic pathways [6]. Even though
CF patients are routinely treated with antibiotics to suppress the infections, high bacterial fitness and
resistance to antibiotics contribute to long-term chronic infections [7]. Metabolism is the currency of
the cell and during the infection it is rewired to accommodate the needs of the cell according to the
environment, the nutrients, and the stresses present in the CF airways [8]. Loss of metabolic functions,
caused by mutations accumulated during the infection, has been proposed to be of selective advantage
in the CF environment. Indeed, P. aeruginosa has a high capability of adapting according to the changing
conditions and the presence of stresses. This makes it successful in colonizing the CF airways for
long time periods and difficult to treat in the clinics. While much attention has been focused on P.
aeruginosa genotypic and phenotypic adaptation, resistance to antibiotics and pathogenesis, the link
between metabolic potential, metabolic adaptation, and a successful infection is still unclear. Here we
review the composition of the CF mucus, the metabolic reorganization of P. aeruginosa during evolution
in CF patients and the metabolic functions active in the CF lung environment. Lastly, we discuss if
metabolic models can contextualize the observed metabolic changes to model the CF environment and
P. aeruginosa lung infection.
2. The Cystic Fibrosis Mucus
2.1. Individual Complexity of the CF Mucus
The CF mucus is a rich complex substrate which provides carbon and energy sources for high
density growth of P. aeruginosa during the infection [5]. A schematic presentation of the CF airway
environment is shown in Figure 1. The abnormal mucus accumulation in the CF lungs is due to
imbalanced ion transport trough the CFTR channel which produces a hyper-concentrated substrate
which strongly adheres to the airway surfaces [3]. The mucus contains high concentrations of mucins,
DNA, free amino acids, glucose, lactate, and ions, which make the substrate highly viscous and very
difficult to analyze using standard chemical and metabolomics techniques [9]. In 2007, Palmer et al.
analyzed 12 sputum samples from adult CF patients with non-exacerbating P. aeruginosa resulting
in a detailed description of the CF mucus composition [10]. Recently, analyses of metabolomes
of longitudinal sputum samples from 11 patients during exacerbations (exacerbation, treatment,
post-treatment, or stable) showed that the individual patients constitute a greater source of variation in
the metabolome composition than the clinical state of the patient [11]. Indeed, the specific metabolite
diversity, the total amino acid content and the concentration of each metabolite vary between samples,
which therefore reveal a high divergence in the mucus composition between patients [10,11]. Moreover,
metabolites, stresses, and antibiotics are not evenly distributed in the distinct regions of the lungs
contributing to high niche complexity [12]. This underlines the individual complexity of the CF
environment, which in turn leads to high bacterial diversity and heterogeneous trajectories of bacterial
evolution [13].
2.2. Composition of the CF Sputum
The CFTR mutation causes unbalanced ion concentrations in the mucus, which can reach around
70 mM in the case of Cl− and Na+ [10]. This disequilibrium makes the CF secretions hyper-saline.
Amino acids are one of the most available nutrients for P. aeruginosa. Moreover, they can be directly
used as building blocks for biomass production or catabolized to generate reducing equivalents [14,15].
The concentration of amino acids in CF sputum, in the range of 5–25 mM, allows high growth rate
and high cellular biomass [5,10]. Analysis of sputum samples from CF and non-CF patients showed
that all amino acids are present in both samples, but CF sputum contains higher concentrations than
non-CF [16]. Glucose is also present in CF and non-CF mucus. The concentration can vary greatly
from patient to patient and during distinct clinical stages, even though the concentration is generally
higher in CF than other pulmonary diseases [10,16,17]. However, although glucose is present in the CF
mucus (range 1.3–4.5 mM) [10], it is not a preferred carbon source for P. aeruginosa, which preferentially
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assimilate amino acids and organic acids over sugars [14]. The CF mucus contains between 3.6 and
15 mM lactate that is likely secreted by neutrophils during anaerobic growth typical of the CF mucus in
the lungs [18]. Similarly, as a consequence of inflammation, neutrophils release high molecular weight
DNA (range 0–9.5 mg/mL), which increases the viscosity of the airways secretions [19,20]. Mucins are
high molecular weight glycoproteins, which form a discontinuous layer in the airways contributing to
protection of the airway epithelium, providing defense against inhaled particles and invading bacteria.
Moreover, they contribute to the high viscosity and the structural complexity of the CF mucus [21].
Their concentration range between 0.1 and 5.7 mM and can be up to 100-fold higher than the DNA
in sputum [22,23]. Even though mucins are an available source of both carbon and nitrogen in the
mucus, P. aeruginosa is unable to catabolize this nutrient [24]. However, while mucins may not directly
contribute to growth of P. aeruginosa in the CF lungs, they do promote diversification in lung-like
conditions underlining the role of nutritional and structural complexity in driving evolution [25].
Pulmonary surfactants, which consist of a mixture of lipids and proteins secreted by the epithelial
cells, play a crucial role in reducing the surface tension at the air/liquid interface in the lungs, which
helps to avoid alveolar collapse at the end of expiration and to ease the breathing [26]. Analysis of
the bronchial surfactant documented a significant heterogeneity of the chemical composition and
distribution in different CF patients. However, in all cases the results pointed to an altered and
dysfunctional composition of the surfactant component due to lung injuries in CF patients [27–29].
Oxygen is often available for P. aeruginosa at limiting concentrations, due to the presence of thick and
viscous mucus in the lungs and to the consumption by immune cells and other members of the lung
microbiota. Direct oxygen measurements in situ using O2 sensors detected steep oxygen gradients
(180–2.5 mmHg) in the mucus, which contribute to micro-aerophilic or even anaerobic conditions [30].
P. aeruginosa can grow both micro-aerobically and anaerobically using nitrate (NO3−) or nitrite (NO2−)
as the final electron acceptors in the electron transport chain and using arginine for fermentation.
Nitric oxide metabolites are widely available in CF sputum (346 µmol/L - 95% CI 311–504) and their
concentration is more than twice that of sputum from healthy individuals [31,32]. These conditions of
reduced oxygen availability induce drastic metabolic changes in P. aeruginosa, which result in increased
antibiotic tolerance, production of virulence factors, biosynthesis of alginate and biofilm development,
ultimately leading to a chronic infection [33].
Figure 1. The cystic fibrosis airway environment. The figure (not to scale) is a schematic representation
of the environment in which Pseudomonas aeruginosa grows which includes nutrients such as amino
acids (aa), lactate (lac), glucose (glu), surfactants (sur), DNA, mucins, and gradients of oxygen (O2).
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2.3. Mimicking the Nutritional Lung-Like Conditions
The need for a medium to recreate the CF environment in vitro, and for studying the physiology
of P. aeruginosa in lung-like conditions, has led the development of the Synthetic CF Medium (SCFM2)
and the Artificial Sputum Medium (ASM), that both mimic the CF sputum composition [10,34,35].
Even though the specific formulations vary between SCFM2 (a defined medium) and ASM (an
undefined medium), both contain all the fundamental components of the CF mucus, and they represent
the gold standards used in many laboratories for investigating P. aeruginosa in a CF context. P. aeruginosa
displays similar phenotypes during growth in CF sputum and in SCFM, including similar growth rates
and gene expression profiles, carbon substrate preferences and cell-to-cell signaling profile [10,35].
However, although it is thus possible to mimic the nutritional lung-like conditions in vitro, it is
still largely unexplored how the composition and concentration of distinct metabolites are spatially
distributed in the mucus, how conditions vary from patient to patient, and to what extent these factors
contribute as drivers for evolutionary trajectories, which lead to chronic infections [12].
3. Diversity of Metabolic Potential over Infection Time
3.1. Heterogeneity of Metabolic Profiles
P. aeruginosa has a wide metabolic repertoire, which allows it to colonize different environments [6].
Although this broad metabolic capacity together with a broad range of virulence factors allow the
bacteria to colonize different niches, the environmental conditions and the availability of nutrients
may limit the use of metabolic pathways to fit the local needs. Nutrient diversity and availability
vary between the lungs and the environment, reshaping the P. aeruginosa metabolic profile during the
infection. Analysis of the metabolic repertoire of clinical strains of P. aeruginosa has shown a broad
metabolic profile heterogeneity, underlining the importance of spatial and chemical diversity in the
environment during evolution in the CF lungs [36–38]. This metabolic heterogeneity is accompanied
by a broader phenotypic and genotypic heterogeneity, which is maximized during the first years of
infection, when adaptive evolution results in reshaping the bacterial physiology in response to the CF
environment [13,39]. In spite of this heterogeneity, parallel changes in bacterial metabolism have been
observed in longitudinal studies, identifying dominant characteristics of long-term adaptive evolution.
A schematic representation of the changes in metabolism of P. aeruginosa during evolution in the CF
environment is presented in Figure 2A.
3.2. Amino Acids Auxotrophies
Auxotrophy is the inability of synthetizing one or more specific metabolites required for growth,
which frequently is observed when such metabolites are widely available in the environment. Amino
acids are valuable carbon sources for P. aeruginosa and the CF mucus is rich in these metabolites.
Analyses of more than 200 sputum samples from 60 CF patients with reduced lung function showed
that in more than 60% of the patients the increased amino acids concentration promoted the
development of auxotrophy from pre-existing prototrophic bacteria [40,41]. Methionine, leucine,
and arginine auxotrophies are frequently observed among clinical CF isolates of P. aeruginosa, and
related non-synonymous mutations in the biosynthetic pathways for these amino acids have been
identified [8,42]. Since amino acid biosynthesis is metabolically ‘expensive’ [43], bacterial loss of the
ability to synthetize them when they are available in the environment, creates a positive selective
advantage of auxotrophic over prototrophic strains [44]. However, while auxotrophy contributes to
high fitness in the CF airways, it limits the ability of P. aeruginosa to move back to environments, where
nutrient availability is often limited.
3.3. Metabolic Rewiring of Clinical Strains
Biolog Phenotype MicroArrays (PMs) are excellent tools to determine global metabolic profiles of
bacteria, and they have also been used for clinical strains of P. aeruginosa. Several such investigations
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have concluded that there is a general reduction of the catabolic repertoire in clinical isolates during
the time of infection [45,46]. Analysis of 35 clinical strains longitudinally isolated from 10 CF patients
during intermittent colonization and chronic lung infection showed that the extensive heterogeneity in
the metabolic profiles observed in early stage isolates is clearly reduced in isolates from later stages [38].
Substrates such as alanine, asparagine, glutamine, arginine, and proline showed the highest reduction
in the catabolic ability over infection time. It is important to note, however, that the PM method
is based on analysis of bacterial catabolism in presence of single substrates. This means that when
observing loss or reduction of the catabolic repertoire, it may be difficult to distinguish between an
actual compromised catabolic pathway, or an impaired unrelated pathway caused for example by
auxotrophy [8,42].
The CF mucus is a complex substrate, requiring more comprehensive metabolomics approaches
to investigate bacterial metabolic evolution during adaptation in the patient. In a study of 179 strains
isolated from 18 CF patients over a 24 years period following the first P. aeruginosa isolation, supernatant
samples from these strains grown in lysogenic broth (LB) were analyzed using Nuclear Magnetic
Resonance (NMR) untargeted metabolomics [37]. Even though only a single supernatant sample after
24 hours of growth was analyzed per strain, this approach resulted in the identification of 32 metabolites
assimilated or secreted by P. aeruginosa. Moreover, the obtained data could be used to determine a
negative correlation between the concentration of seven metabolites and the length of infection. As an
example, acetate was observed to be secreted at higher concentrations from isolates with short infection
age compared with long-term adapted strains. Amino acids such as phenylalanine, tryptophan,
tyrosine, valine, lysine, and serine showed either reduced excretion or increased consumption over
time. These results suggest that CF clinical strains evolve towards a more complete utilization of
metabolically costly compounds relative to other compounds [37]. However, strains isolated from
distinct patients showed the highest degree of variability in metabolite levels, in accordance with
an individual composition and structure of the CF lung environment and consequential distinct
trajectories of within-patient evolution [11,37].
To characterize the metabolic specialization developing during long-term infection, six clinical
isolates of P. aeruginosa, representing different stages of evolution (naïve, intermediate, and adapted),
were isolated from sputum samples collected from one CF patient over a period of 8 years of infection [8].
Using a metabolic footprinting approach [47,48], where multiple supernatant samples were collected
during the growth in LB medium and analyzed by targeted metabolomics, a time-dependent map
of the metabolic requirement and preference of the strains was created. When compared with naïve
strains, the adapted strains showed: (1) auxotroph phenotypes due to mutations in biosynthetic genes
for amino acids; (2) a preference of assimilation of carbon sources distinct from the one of naïve
strains designed for the CF lung resources; (3) reduced arginine and pyruvate fermentation processes;
(4) reduced acetate secretion; and (5) increased oxygen requirement [8]. A schematic representation
of the metabolic behavior of naïve strains compared with adapted strains of P. aeruginosa is shown
in Figure 2A. In brief, analysis of the assimilation and secretion patterns showed that assimilation of
four metabolites was reduced in the adapted strains, suggesting selective assimilation. Three amino
acids were indispensable substrates for growth of the adapted strains due to auxotrophy. Assimilation
of five metabolites was conserved, since no differences in the assimilation patterns between naïve
and adapted strains were observed. Altered assimilation patterns in the adapted strains for five
amino acids and organic acids were shown as differential substrate uptake during the exponential and
stationary phases according to the degree of adaptation. Due to different distributions of metabolic
fluxes and fermentation processes, naïve and adapted strains showed selective secretion profiles for
five metabolites. The assimilation of oxygen, the concentration of which fluctuates in the CF sputum,
was reduced in adapted strains (Figure 2A) [8]. While both the naïve and the adapted clinical isolates
maintained their metabolic profiles during 8 years of adaptation in the patient, the intermediate strains
showed both characteristics, indicating transition from the naïve to the adapted stage. This work
shows how the adaptive changes occurring during evolution in the CF environment support the idea of
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parallel evolution of metabolism. However, attempts to align the metabolic profiles with the mutations
identified in the genomes failed to identify causality for the observed phenotypes due to high numbers
of mutations and the complexity of the regulatory networks governing metabolism [8].
3.4. Mutations on Non-Metabolic Genes Causing Metabolic Changes
Many mutations accumulated in P. aeruginosa genomes during infections in the airways of CF
patients have been characterized both molecularly and phenotypically [49,50]. However, the metabolic
costs and consequences of most mutations are largely unknown. In fact, it is unclear if metabolic
adaptation is specifically selected for in vivo, or if it indirectly develops as consequence of other
unrelated mutations. Metabolism is highly regulated and changes in distant regulatory networks or
changes in the expression of metabolic enzymes can have a broad metabolic impact independently of
mutations in metabolic genes [15]. One of the main regulators of the P. aeruginosa quorum sensing
system (QS) – LasR – activates the expression of many virulence factors [51–53]. The lasR gene is
under strong selective pressure, and many mutations in this gene have been identified in clinical
strains from both young and adult patients [39,53–56]. LasR mutants undergo a dramatic metabolic
shift associated with a growth advantage in presence of specific amino acids and nitrate as nitrogen
source, which are both abundant in the CF mucus. Moreover, LasR mutant strains show decreased
oxygen consumption and increased tolerance to tobramycin and ciprofloxacin, which are routinely
used for the treatment of P. aeruginosa infections in CF patients [55,56]. Similarly, inactivation of
both the lasR and rhlI genes, responsible for the production of two of the most important QS signals
in P. aeruginosa, causes a global metabolic rearrangement of the cell with changes in the cellular
exo-metabolome, perturbations in the tricarboxylic acid (TCA) cycle intermediates, amino acids, and
fatty acids metabolites, resulting in reorganization of the cellular metabolic fluxes [57]. Increased
antibiotic resistance caused by overexpression of multidrug-resistant (MDR) efflux pumps is an
important survival strategy for P. aeruginosa in the CF environment [58]. In the case of the MexEF-OprN,
MexAB-OprN, MexCD-OprJ, and MexXY pumps, it has been shown that to compensate for the fitness
cost of overexpressing these costly transporters, bacteria increase nitrate consumption and enhance
oxygen uptake to counterbalance the intracellular H+ accumulation [59,60]. Even though the examples
above have mainly been reported for P. aeruginosa laboratory strains, they all suggest that rewiring
of metabolism may occur as a compensatory mechanism for metabolically unrelated changes in
other traits.
In conclusion, it is still unclear if bacterial metabolic adaptation should be seen as a response to
nutrient availability within the host environment, or if it is an indirect fitness consequence of mutations
in genes responsible for unrelated phenotypes.
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Figure 2. Metabolic reorganization of Pseudomonas aeruginosa during patient evolution. (A) The figure
represent the metabolic configuration of adapted strains compared to naïve strains where metabolites
show: selective assimilation (succinate, glucose, valine, and ornithine); indispensable assimilation
due to auxotrophy (arginine, leucine, and methionine); conserved assimilation pattern (asparagine,
glycerol, serine, alloisoleucine, and leucine); altered assimilation pattern (aspartate, acetate, glutamate,
lactate, and pyruvate); selective secretion (acetate, ornithine, pyruvate, lactate, and glycine); reduced
assimilation (oxygen) [8]. A detailed description of the changes in metabolic profiles during evolution
is presented in paragraph 3. (B) In vivo metabolic program of P. aeruginosa. Genes upregulated in vivo
relative to in vitro are represented in red, genes downregulated in blue, and genes which expression
is constant in both conditions are in gray [61]. Compounds assimilated during exponential phase by
adapted clinical strains of P. aeruginosa are indicated in green [8]. The dotted lines represent related
metabolic pathways connected to the assimilated compounds.
4. Pseudomonas aeruginosa In-Situ Metabolic Program
4.1. In Vitro vs. in Situ Expression Profiles
Adaptive processes occurring in the CF lung environment using whole genome sequencing (WGS)
of strains isolated from CF patients have been described previously [39,62,63]. Pathoadaptive
mutations in evolutionary important genes have been characterized in clinical isolates from
longitudinal collections of P. aeruginosa [39]. This pattern of genomic convergence, however, has
been challenged by extensive phenotypic diversity, which has limited our ability to predict specific
outcomes of mutations [13]. Moreover, different lineages showing individual genomic patterns
often display similar phenotypes or similar expression profiles, independently of the accumulated
mutations [46,61,64–66]. These observations create severe challenges for predictions of infection
outcome based on genome sequencing.
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To overcome some of these problems, direct investigations of bacterial expression profiles in
sputum samples from individual patients have been used to obtain insight in the in situ lifestyle of
P. aeruginosa in the host. Due to the characteristics of the CF mucus, the dynamics of the CF airway
environment, and the interference from host cells, only few conclusive results are available [61,67–69].
Both RNA-seq and proteomics based approaches have been employed to provide snapshots of the
bacterial metabolic profiles in the lungs of CF patients. For relative quantification of specific RNAs
and proteins in sputum samples, comparisons of the expression profiles in situ (metatranscriptome or
metaproteome) with the expression profiles in vitro in laboratory conditions of isolated strains from
the same sputum sample were carried out. In one investigation, the global gene expression profiles
(patho-phenotypes) of P. aeruginosa were determined in 15 sputum samples from five chronically
infected CF patients [61], and as expected the transcriptomic signatures of the soft-core genomes
in situ differed from the ones of the lab conditions [61]. Interestingly, the soft-core genome global
expression profiles were surprisingly similar, independent of lineage and host specific characteristics,
suggesting that adaptation to the CF lung involves a defined set of regulatory processes, which govern
the core physiology and behavior of the bacterial populations with little impact from the clonal and
genomic variance, the host environment and competing microorganisms. Analyses of transcriptomic
profiles from five different regions of an ex vivo explanted CF lung showed reduced expression
profile diversities within the individual regions independent of the genetic variation of the isolated
strains [66]. Similar results were obtained when comparing proteomes of 35 sputum samples from
11 CF patients [67]. Both meta-transcriptomic and meta-proteomic investigations of very complex
samples have inherent technical problems, but both identify very similar in vivo configurations of
metabolism, which differ from those observed in laboratory conditions. A schematic representation of
the in vivo metabolic program of the cell is shown in Figure 2B.
4.2. Metabolic Configuration in the CF Airways
Changes in the physiology of the cells in situ converge to a general narrowing of the cellular activity
as suggested by the reduced growth rate described in vivo [70]. Even though glucose is present at high
concentration in CF mucus, P. aeruginosa shows reduced sugar metabolism caused by the repression of
the gltBFK-oprB genes encoding the glucose transport system [61]. Glucose is a less preferred carbon
source for P. aeruginosa and the loss of assimilation of this compound has also been described by
metabolic footprinting analysis of clinical isolates [8,14]. Moreover, reduced expression of pyruvate
carboxylase and pyruvate dehydrogenase, transforming pyruvate into oxaloacetate and acetyl-CoA,
respectively, suggests that P. aeruginosa employs a gluconeogenic rather than a glycolytic metabolic
configuration (Figure 2B) [61]. Furthermore, aceE and aceF, encoding pyruvate dehydrogenase, are
among the pathoadaptive genes, which are frequently mutated in clinical isolates [39]. This metabolic
rewiring is further supported by an increased expression of the lactate dehydrogenase (lldA), which
replenishes the pool of pyruvate, necessary for the gluconeogenic processes, from lactate. Proteomic
analysis of P. aeruginosa in sputum samples showed an increase in the abundance of the lldP lactate
permease, confirming the meta-transcriptomic results [67]. Lactate is abundant in the CF mucus, and
it is used both by naïve and adapted strains, although the time of assimilation changes according
to the adaptive stage [8,10]. Interestingly, in E. coli disruption of the pyruvate dehydrogenase
complex causes resistance to certain type of chemokines with antimicrobial effects, which may also
be the case in CF lungs with P. aeruginosa being targeted by those chemokines [71]. Expression
of the genes coding for the lower part of the TCA cycle, such as oxoglutarate dehydrogenase and
succinyl-CoA (sucA, sucC, and lpd genes), were found to be repressed in situ relative to in vitro.
In contrast, isocitrate lyase (aceA) expression transforming isocitrate into glyoxylate was increased
in situ, indicating a higher activity of the glyoxylate shunt rather than the decarboxylation steps of
the TCA cycle [61]. Interestingly, expression of the C5-dicarboxilic acid transporter was increased
in situ, indicating that α-Ketoglutarate, which is part of the decarboxylation steps of the TCA cycle,
might be used to protect the cells from oxidative stress and cyanide poisoning, or to regulate nitrogen
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metabolism through the nitrogen regulator PII [61,72]. However, α-Ketoglutarate has not been
identified in sputum samples [10]. Expression of fumarate hydratase (fumC1), which catalyzes the
interconversion of fumarate and malate and modulates the redox balance, was increased in both the
meta-transcriptomic and the meta-proteomic profiles, consistent with the presence of reactive (RNS)
and oxidative (ROS) stresses in the lung environment [61,67,73]. Therefore, amino acids are likely
carbon sources for biomass production, and the TCA cycle and the glyoxylate shunt produce ATP and
the reducing equivalents (NADH and FADH2) necessary to counterbalance the stresses present in the
lung environment. In support of the hypothesis that amino acids are the main carbon sources in vivo,
genes coding for amino acid permeases (PA2202, PA2079, PA2041, and PA1916) were found to be
expressed at higher levels in situ compared to laboratory conditions [61]. Moreover, analysis of ex vivo
samples of an explanted CF lung showed that amino acid biosynthetic pathways were down-regulated
relative to in vitro [66]. Overall, processes such as ATP synthesis coupled electron transport, cellular
lipid metabolism, fatty acid biosynthesis, propionate metabolism, oxoacid metabolism, isoprenoid
catabolism, oxidative phosphorylation, and fatty acid and phospholipid metabolism, were shown to be
down regulated ex vivo compared to laboratory conditions, reflecting the low energy and slow growth
phenotype of P. aeruginosa cells growing in the CF environment [66].
It is worth noting, that although transcriptomic and proteomic data are informative about relative
abundances of mRNA and proteins, helping our understanding of the environmentally determined
global cellular phenotypes, such data do not directly translate into metabolic fluxes. This leaves a
gap between the metabolic potential of the cell and the actual cellular metabolism. Therefore, further
investigations, new technologies and new approaches are needed to fully characterize the metabolic
processes of P. aeruginosa when living in the CF mucus.
5. Modelling the CF Dynamics in Silico
CF is a complex genetic disorder associated with a favorable environment rich in nutrients,
a diverse polymicrobial infection competing for survival, presence of antibiotics, other stresses,
challenges from the host immune system, and a non-uniform distribution of all these components
in different compartments of the CF airways. This scenario drives rapid evolution of P. aeruginosa
through the CF evolutionary landscape, which creates heterogeneous solutions, multiple outcomes, and
clonal diversity. While in vivo and in vitro studies are fundamental to understand and characterize P.
aeruginosa adaptation and evolution in the patients, we are still a long way from identifying diagnostic
markers useful for classification of the infection development and for predicting consequences of the
infections. Can we use in silico methods to predict pathogen dominance, virulence, and antibiotic
resistance profiles? Can we recreate in silico the CF environment [74]? Genome-scale metabolic network
models are useful tools that allow one to simplify complex biological networks in biological and
metabolic functions that can be quantified and predicted statistically. Moreover, metabolic models can
predict data such as uptake and secretion rates, metabolite exchanges between species, and competing
or cooperative relationships difficult to analyze in vivo [75].
Virulence-linked pathways and gene essentiality of P. aeruginosa PAO1 and PA14 have recently
been modeled using genome-scale metabolic network reconstructions, which provide the most
comprehensive representation of P. aeruginosa metabolism [76]. The models account for the function of
1129 and 1146 genes, 1495 and 1493 reactions, and 1286 and 1284 metabolites, respectively, for PA14
and PAO1 strain. Bartell et al. were able to link the contribution of metabolic genes to virulence
factors, and to define the essential genes which link virulence factor synthesis and cellular growth
at a systemic level [76]. These results could have great implications for targeting virulence-related
pathways with respect to drug development for treatment of resistant bacteria [77]. However, it is
unclear whether in silico genome-scale metabolic network models are relevant for clinical strains with
hundreds of mutations and strain specific metabolic configurations. Recently, Henson et al. developed
a metabolic model of CF airway communities in order to predict pathogen dominance based on the
17 most abundant bacterial taxa in sputum samples [78]. Using this approach, the authors were
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able to predict interactions between species mediated by competition for host-derived nutrients and
cross-feeding of secreted metabolites, and to match the abundance of the different species from 16S
rDNA sequencing data. Moreover, since it is not possible to analyze the uptake and secretion rates
of metabolites in situ, and since many of the cross-feeding metabolites might be only present in the
close proximity of the community and not detectable in sputum samples, the authors computed the
uptake and secretion rates and compiled a list of additional metabolites required for the maintenance
of such in silico communities [78]. However, there is considerable skepticism concerning the use of
these methods, because it is still unclear if the principles for maintaining the in silico communities
are valid also in vivo, and if the available metabolic models are adequate and relevant for predicting
outcomes of infections.
6. Conclusions
CF airways are complex and highly structured environments, in which Pseudomonas aeruginosa is
subjected to steep gradients of nutrients and to stresses of various types, and in which the bacteria
optimize over time their physiology in response to the immediate surroundings. Patient to patient
variations and different treatment regimens influence how adaptation of P. aeruginosa progresses, and
which phenotypic solutions it develops. Therefore, heterogeneity is a characteristic of both the airway
environment and the P. aeruginosa populations evolving in the patients. Moreover, bacteria with distinct
phenotypic characteristics co-exists in the CF airways suggesting that metabolic adaptation may also
account for competition for nutrients. For their accessibility, studies on single bacterial isolates have
been extensively carried out, but they are insufficient to explain how a whole population behave in
the CF airways. Indeed, social interactions between bacteria can change their metabolic profiles to
account for collaboration or competition for the available nutrients [79,80]. Unfortunately, predictions
on how different isolates co-habiting the same niche grow and how metabolism proceed in presence of
a polymicrobial community is very difficult to evaluate both in vivo and in vitro. This leaves a gap
that could be filled by the use of metabolic models that account for both population dynamics and
social interactions and by extensive studies of bacterial metabolism.
However, despite the diversity of phenotypes and the many different evolutionary trajectories,
phenotypic convergence occurs, suggesting that specific traits are generally selected for in vivo to
increase bacterial fitness and subsequent persistent infections. Among these convergent phenotypes,
reduced growth rate is a striking feature of many clinical strains, both in vivo and in vitro [8,13,37,70].
Slow growth is a phenotype with a complex causality that promotes increased resistance to antibiotics
and persistence for many bacterial species [81,82]. Independently of the mechanism, a correlation
between growth rate and ciprofloxacin and streptomycin susceptibility, and between growth rate and
bacterial persistence, has been described for both Escherichia coli and Salmonella enterica [83–85]. In the
CF lung environment, slow growth may be a consequence of the described metabolic specialization,
but it is also likely that mutations in global regulators may cause pleiotropic effects on other unrelated
traits with resulting fitness costs. Certainly, reduction of cellular metabolic activities seems to favor the
infection state of P. aeruginosa by increasing its fitness in the CF airway environment [61,66]. Antibiotics
often target central cellular processes, which are essential for growth. Mutations which alter the normal
coordination of growth, as for example by disrupting central cellular processes such as replication,
transcription, and translation, may trigger increased tolerance to antibiotics and a persistent phenotype
showing a reduction of the metabolic functionality of the cell.
It has been proposed to use metabolic processes as targets for next generation antibiotics and to
use metabolism to resuscitate persistent cells [86]. Moreover, metabolic profiling of clinical strains
may be also used as a diagnostic of the infection state. However, this requires extended in-depth
investigations of the CF sputum metabolome to unfold the metabolite complexity and the differences
between patients. Indeed, metabolites activity as antibiotic potentiators strongly depends on the
specific metabolic profiles of clinical isolates [87]. Additional in vitro studies of cellular metabolism
under in vivo like conditions can also help to clarify the metabolic specificities of clinical isolates, and
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new and better model systems, which recreate the physiology and complexity of the CF environment,
are needed for detailed assessments of interference by new potential antagonists. A detailed review of
antibiotic tolerance and metabolic adaptation can be found in [86]. Moreover, for eventual translation
of research results to useful clinical applications, we need new strategies to understand and recreate in
silico the CF environment with its complexity, its heterogeneity in metabolite composition, stresses,
antibiotics, and bacterial species, to predict infection progression and evolutionary trajectories of the
infecting microbes.
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